← Back to Search

Intravenous Ketamine for Major Depressive Disorder

Phase 3

Waitlist Available

Led By Pierre Blier, MD, PhD

Research Sponsored by University of Ottawa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3-4 weeks

Awards & highlights

Study Summary

This trial will compare the effects of electroconvulsive therapy (ECT) and ketamine in people with depression who haven't responded to other treatments.

Eligible Conditions

Depression
Major Depressive Disorder
Depression, Bipolar Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3-4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3-4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Montgomery-Asberg Depression Rating Scale

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intravenous KetamineExperimental Treatment1 Intervention

Group II: Electroconvulsive TherapyActive Control1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ontario Shores Centre for Mental Health SciencesOTHER

12 Previous Clinical Trials

1,898 Total Patients Enrolled

Queen's UniversityOTHER

365 Previous Clinical Trials

120,177 Total Patients Enrolled

University Health Network, TorontoOTHER

1,468 Previous Clinical Trials

484,279 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many different places are currently running this experiment?

"Right now, there are 5 sites where this clinical trial is enrolling patients. If you're considering participating in the study, choose the site that's closest to you to minimize travel time and inconvenience."

Answered by AI

Has the FDA cleared intravenous ketamine for therapeutic use?

"There is pre-existing clinical evidence to support Intravenous Ketamine's efficacy and safety, so it received a score of 3."

Answered by AI

Is this experimental treatment still enrolling individuals?

"Yes, this is an ongoing clinical trial that was originally posted on October 29th, 2018. The latest update occurred on April 14th, 2021. They are currently recruiting for 240 patients from 5 different locations."

Answered by AI

How many people are subjects in this trial?

"The clinical trial is recruiting for 240 participants across 5 locations."

Answered by AI

Are middle-aged individuals qualified to participate in this testing?

"According to the posted inclusion criteria, eligible patients for this particular clinical trial fall between 18-70 years old. There are a total of 231 trials for individuals under 18 and 1147 for adults over 65."

Answered by AI

Who might be eligible to join this clinical trial?

"This clinical trial is admitting 240 people, within the ages of 18 and 70 who currently have psychosis, involutional. Patients must also meet the following criteria: Be able to understand and comply with the requirements of the study, as judged by the investigator(s)., Men and women aged between 18 and 70 years, inclusive with a body mass index (BMI) < 35. They must have a Montreal Cognitive Assessment (MOCA) score ≥ 24., Patients meeting criteria for Major Depressive Disorder (MDD) or Bipolar disorder (BP) without psychotic symptoms according to the Diagnostic and Statistical Manual for Mental Disorders"

Answered by AI

Recent research and studies

BMC PsychiatryJournal

A Randomized, Crossover Comparison of Ketamine and Electroconvulsive Therapy for Treatment of Major Depressive Episodes: A Canadian Biomarker Integration Network in Depression (CAN-BIND) Study Protocol

Phillips, Jennifer L., Natalia Jaworska, Elizabeth Kamler, Venkat Bhat, Jean Blier, Jane A. Foster, Stefanie Hassel, et al.. 2020. “A Randomized, Crossover Comparison of Ketamine and Electroconvulsive Therapy for Treatment of Major Depressive Episodes: A Canadian Biomarker Integration Network in Depression (CAN-BIND) Study Protocol”. BMC Psychiatry. Springer Science and Business Media LLC. doi:10.1186/s12888-020-02672-3.

clinicaltrials.govStudy

Ketamine Versus Electroconvulsive Therapy in Depression

Pierre Blier 2018. "Ketamine Versus Electroconvulsive Therapy in Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03674671.